Literature DB >> 30741468

INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study.

Alban Comet1, Pierre Gascon1,2, Lauren Sauvan1, Benjamin Donnadieu1, Frédéric Matonti1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30741468     DOI： 10.1111/aos.14057

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  4 in total

1.  Comparison of intravitreal aflibercept and dexamethasone implant in the treatment of macular edema associated with diabetic retinopathy or retinal vein occlusion: a Meta-analysis and systematic review.

Authors:  Xuan-Yu Qiu; Xiao-Fei Hu; Ya-Zhou Qin; Ji-Xian Ma; Qiu-Ping Liu; Li Qin; Jing-Ming Li
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

2.  Intravitreal steroids for macular edema in diabetes.

Authors:  Thanitsara Rittiphairoj; Tahreem A Mir; Tianjing Li; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-11-17

3.  Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes.

Authors:  Javier Zarranz-Ventura; Barbara Romero-Núñez; Carolina Bernal-Morales; Daniel Velazquez-Villoria; Anna Sala-Puigdollers; Marc Figueras-Roca; Sergio Copete; Laura Distefano; Anna Boixadera; Jose García-Arumi; Alfredo Adan
Journal:  BMC Ophthalmol       Date:  2020-11-11       Impact factor: 2.209

4.  Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study).

Authors:  Pierre Gascon; Isabelle Borget; Alban Comet; Laurence Carton; Frédéric Matonti; Laure Dupont-Benjamin
Journal:  Eur J Ophthalmol       Date:  2021-07-20       Impact factor: 1.922
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.